Vertical: CNMBase Year: 2025
Market Size (2025)
$20.75M
Projected (2032)
$30.71M
CAGR (2022–2032)
5.8%
Key Players
9+
Market Overview
The Global Cypermethric Acid Chloride Market was valued at USD 20.75 Million in 2025 and is projected to reach USD 30.71 Million by 2032, registering a CAGR of 5.75% during 2026–2032. Between 2025 and 2032 the market is expected to add USD 9.97 Million in absolute value. The market expanded from USD 17.47 Million in 2022 to USD 19.60 Million in 2024, reflecting steady consumption of the intermediate by synthetic pyrethroid manufacturers.
Cypermethric acid chloride (CMAC), also referred to as DV acid chloride or permethric acid chloride, is the acid-side building block for a family of Type I and Type II synthetic pyrethroids, including cypermethrin, alpha-cypermethrin, beta-cypermethrin, zeta-cypermethrin, permethrin and cyfluthrin. Demand for the intermediate is therefore a direct function of pyrethroid technical output, which is concentrated in India and China, and of end-use demand for these insecticides in agriculture, public health vector control, household pest control and animal health.
Key Findings
By Downstream Product: Cypermethrin was the largest segment in 2025 at USD 14.52 Million (70.00% share), while Permethrin & Others is the fastest-growing segment with a CAGR of 6.94% over 2026–2032.
By Purity: The 98% & Above grade led the market in 2025 with USD 16.60 Million (80.00% share) and is also the fastest-growing grade at a CAGR of 6.08%.
By Region: Asia Pacific was the leading region in 2025 at USD 16.18 Million (78.00% share), while Middle East & Africa is the fastest-growing region with a CAGR of 7.73%.
By Country: China was the leading country in 2025 at USD 7.28 Million, accounting for 35.10% of the global market. Saudi Arabia is the fastest-growing country with a CAGR of 8.48%, followed by UAE at 8.39% and India at 8.01%.
Segmentation Summary
The market is segmented by downstream product (Cypermethrin; Permethrin & Others), by purity (98% & Above; Below 98%) and by region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa), with country-level analysis within each region. Cypermethrin accounts for 70.00% of 2025 demand because it remains one of the most widely used generic insecticides in cotton, vegetables, pulses, rice and soybean. The Permethrin & Others segment, which includes permethrin and other CMAC-derived pyrethroids such as cyfluthrin, is growing faster at a CAGR of 6.94%, supported by public health, household and veterinary applications. High-purity material (98% & Above) represents 80.00% of demand in 2025 as producers of isomer-enriched actives such as alpha- and beta-cypermethrin require tightly specified feedstock.
Competitive Landscape Summary
The market is moderately consolidated. Production of CMAC requires multi-step chlorination and cyclopropanation chemistry, hazardous-material handling and environmental clearances, which limits the number of credible producers. Most CMAC is produced captively by integrated synthetic pyrethroid manufacturers, with a smaller merchant market serving non-integrated technical producers. Indian producers, including Gharda Chemicals, Tagros Chemicals India, Hemani Industries, Heranba Industries and the Vapi operations of Bayer, together with Chinese producers led by Jiangsu Yangnong Chemical, form the core of the competitive landscape. Competition is primarily based on cost, backward integration, isomer control and regulatory dossiers held for downstream actives.
Challenges and Opportunities
The principal challenges are regulatory tightening of pyrethroids in developed markets, rising insect resistance to pyrethroids, and the cost of complying with environmental and process-safety standards for chlorination chemistry. Trade remedies have also become a factor: in May 2025 China imposed definitive anti-dumping duties of between 48.4% and 166.2% on cypermethrin imported from India, redirecting Indian export volumes towards other markets. Opportunities include capacity additions and backward integration in India, growing demand for high-cis and high-purity grades, and expanding consumption in Latin America and Middle East & Africa, where agricultural intensification and vector-control programmes support pyrethroid use.
Future Outlook
The market is expected to maintain mid-single-digit growth through 2032, reaching USD 30.71 Million. Asia Pacific will remain the centre of both production and consumption, with its value rising from USD 16.18 Million in 2025 to USD 24.00 Million in 2032. Growth in Europe (4.65%) and North America (4.84%) is expected to be slower due to regulatory constraints on pyrethroid use, while Middle East & Africa (7.73%) and Latin America (6.94%) are expected to outpace the global average. Over the forecast period, the share of high-purity material is projected to rise from 80.00% in 2025 to 81.75% in 2032, reflecting the industry shift towards isomer-enriched pyrethroids.
The Cypermethric Acid Chloride Market market is projected to grow at a CAGR of 5.8% from 2022 to 2032.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansDefinition
Cypermethric acid chloride (CMAC) is the common trade name for 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropane-1-carbonyl chloride (CAS No. 52314-67-7; molecular formula C8H9Cl3O). It is the acid chloride of cypermethric acid (DV acid), a substituted cyclopropanecarboxylic acid that forms the acid moiety of several synthetic pyrethroid insecticides. CMAC is typically supplied as a clear, pale yellow to brown liquid and is characterised by its assay and by its cis:trans isomer ratio, which determines the isomer composition of the downstream pyrethroid. Standard grades carry cis:trans ratios close to 50:50 or 40:60, while high-cis grades are produced for alpha-cypermethrin and related isomer-enriched actives.
In commercial production, CMAC is esterified with the cyanohydrin of 3-phenoxybenzaldehyde to produce cypermethrin and its isomer-enriched variants, with 3-phenoxybenzyl alcohol to produce permethrin, and with the cyanohydrin of 4-fluoro-3-phenoxybenzaldehyde to produce cyfluthrin.
Included in the scope: CMAC of all grades and isomer ratios, whether consumed captively by integrated pyrethroid producers or traded on the merchant market, valued at the intermediate stage and classified by downstream product, purity and geography.
Excluded from the scope: the downstream pyrethroid technicals and formulations themselves; precursor intermediates such as DV ester and free DV acid when sold as such; and acid chlorides used for other pyrethroids, such as the dibromovinyl acid chloride used for deltamethrin and the trifluoromethyl-substituted acid chloride used for lambda-cyhalothrin.
Research Objectives
To estimate and forecast the size of the global cypermethric acid chloride market in value terms (USD Million) for 2022–2032.
To analyse demand for CMAC by downstream product, distinguishing consumption for cypermethrin from consumption for permethrin and other CMAC-based pyrethroids.
To assess the market by purity grade and evaluate the shift towards high-purity and isomer-enriched material.
To quantify regional and country-level demand and identify the fastest-growing geographies across five regions and their constituent countries.
To evaluate the drivers, restraints, opportunities, trends and challenges affecting CMAC demand, including regulatory and trade developments for pyrethroids.
To map the value chain from raw materials through CMAC synthesis and pyrethroid manufacturing to end-use applications.
To profile the competitive structure, identify leading producers and track capacity additions, trade actions and corporate developments since 2022.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansOverview of the Research Process
The study followed a structured research process comprising scoping, data collection, market estimation, validation and report preparation. The market was first defined at the level of the intermediate, and its relationship to downstream pyrethroid technicals was mapped. Secondary research established the production base, trade flows, regulatory environment and demand for downstream insecticides. Primary research with participants across the value chain was used to validate assumptions on consumption ratios, grade mix, pricing and regional demand. The resulting estimates were triangulated and reviewed for internal consistency before being finalised.
Secondary Research
Secondary research drew on sources specific to the agrochemical intermediates and synthetic pyrethroid industry, including:
Industry associations: crop protection and agrochemical manufacturer associations in India, China, Europe and the Americas, and associations representing public health pest control and vector-control product suppliers.
Government and regulatory bodies: pesticide registration authorities (such as the U.S. EPA, the European Commission and ECHA, India's Central Insecticides Board and Registration Committee, and China's Institute for the Control of Agrochemicals), trade remedy authorities, and environmental clearance records for manufacturing projects.
Company filings: annual reports, investor presentations, stock exchange disclosures, credit rating rationales and environmental statements of pyrethroid and intermediate manufacturers.
Trade journals and publications: agrochemical industry news services, chemical trade publications and specialist reports on generic crop protection active ingredients.
Trade and paid databases: customs and export–import statistics for pyrethroid intermediates and technicals, and commercial company and chemical pricing databases.
Primary Research
Primary research was conducted through in-depth interviews with participants on both the supply and demand sides. On the supply side, respondents included production, technical and commercial managers at CMAC and pyrethroid technical manufacturers, as well as traders and distributors of agrochemical intermediates. On the demand side, respondents included procurement and formulation managers at pyrethroid formulators, public health product suppliers and animal health product manufacturers, along with independent industry experts. The objectives were to validate consumption ratios of CMAC per unit of downstream pyrethroid, confirm purity grade preferences, understand pricing and contracting practices, and obtain views on capacity additions, regulatory developments and regional demand trends.
Market Size Estimation
Top-down approach: Global and regional demand for CMAC-based pyrethroids (cypermethrin and its isomers, permethrin and others) was estimated from pesticide consumption and trade data. Downstream volumes were converted into CMAC requirements using stoichiometric and yield-adjusted consumption factors, and then valued using grade-specific average selling prices.
Bottom-up approach: Installed and operating capacities of identified CMAC and pyrethroid technical producers were compiled, adjusted for utilisation rates and captive versus merchant use, and aggregated to derive supply-side estimates by region.
Data triangulation: The top-down and bottom-up estimates were reconciled with each other and with insights from primary interviews. Differences were resolved by re-examining conversion factors, price assumptions and regional allocations until a consistent market estimate was achieved.
Forecasting Methodology
Forecasts were developed by projecting demand for each downstream product and purity grade at the regional and country level. Factors considered include crop acreage and pest pressure in key pyrethroid-consuming crops, public health and vector-control programme requirements, regulatory decisions on pyrethroid approvals and use restrictions, capacity additions and trade measures, raw material cost trends and the shift towards isomer-enriched products. Each factor was assessed for its impact over the short, medium and long term, and the forecasts were reviewed against expert opinion.
Base Year, Forecast Period and Currency
Historic years: 2022, 2023 and 2024
Base year: 2025
Forecast period: 2026–2032 (CAGR calculated for 2026–2032)
Currency: All values are presented in USD Million.
Assumptions and Limitations
Market values are based on average annual exchange rates and reflect nominal prices at the intermediate stage.
Captively consumed CMAC is valued at estimated merchant-equivalent prices so that integrated and non-integrated production are treated consistently.
Regional values reflect consumption of CMAC by pyrethroid manufacturers located in each region rather than the location of final insecticide use.
The forecast assumes no major new bans on cypermethrin or permethrin in large consuming markets during the forecast period beyond decisions already published.
Private producers do not disclose CMAC-specific capacity or output, so some supply-side inputs rely on estimates validated through primary research.
Trade policy changes, raw material shocks or unforeseen regulatory actions could cause actual outcomes to differ from the forecasts.
Base Year
2025
Historical Period
2022 – 2024
Forecast Period
2026 – 2032
Primary Interviews
150+
Historical data (2022–2025) and forecast period (2025–2032)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansIntroduction
The global cypermethric acid chloride market is moderately consolidated, with production concentrated among a limited number of integrated synthetic pyrethroid manufacturers in India and China. Most CMAC is produced for captive consumption in the same company's cypermethrin, permethrin and related pyrethroid plants, and only a portion is sold on the merchant market to non-integrated technical producers and formulators. Barriers to entry are significant because of the complexity of the chemistry, the need to control isomer ratios and impurity profiles, and the environmental clearances required for chlorination processes.
Competition is driven mainly by production cost, the degree of backward integration into raw materials and alcohol-side intermediates, product quality and grade range, reliability of supply, and the strength of regulatory dossiers held for downstream actives. Trade policy has become an additional competitive variable: in May 2025 China imposed definitive anti-dumping duties on cypermethrin from India, with company-specific rates of 48.4% for Tagros Chemicals India, 62.0% for Meghmani Organics, Bharat Rasayan and Heranba Industries, 75.7% for Gharda Chemicals, and 166.2% for UPL and all other Indian producers.
Key Player Positioning
Leaders: Gharda Chemicals, Jiangsu Yangnong Chemical, Tagros Chemicals India, Hemani Industries and Bayer (through Bayer Vapi Private Limited) are positioned as market leaders. Gharda Chemicals manufactures standard, high-cis and low-cis CMAC grades and reported revenue of INR 3,619 crore in FY2025. Jiangsu Yangnong Chemical, part of Syngenta Group, is China's leading pyrethroid producer and reported revenue of CNY 11.87 billion in FY2025; it accounted for the majority of Chinese cypermethrin output according to its anti-dumping application. Tagros Chemicals India is an export-oriented pyrethroid specialist that produces DV acid chloride. Hemani Industries produces both CMAC and 3-phenoxybenzaldehyde, giving it integration across both halves of the cypermethrin molecule. Bayer's Vapi site in India is a backward-integrated pyrethroid manufacturing hub that uses CMAC to produce a range of pyrethroid actives; Bayer AG reported group sales of EUR 45.6 billion in FY2025.
Challengers: Heranba Industries, Meghmani Organics, Bharat Rasayan and UPL are positioned as challengers. Heranba Industries manufactures CMAC, including a high-cis grade, and cypermethrin technical, with revenue of about INR 1,595 crore in FY2026. Meghmani Organics is a major producer of cypermethrin and other pyrethroid technicals, with consolidated revenue from operations of INR 2,173.9 crore in FY2026. Bharat Rasayan produces pyrethroid technicals and the alcohol-side intermediate 3-phenoxybenzaldehyde, with revenue of about INR 1,242 crore in FY2026. UPL, with revenue of INR 51,839 crore in FY2026, is a major global agrochemical company and an exporter of cypermethrin, for which pyrethroid generics form a small part of a broad portfolio.
Niche players: Chinese cypermethrin producers such as Guangdong Liwei Chemical, Guangdong Guangkang Biochemical and Shandong Huayang Agrochemical, together with smaller regional technical manufacturers, traders and merchant intermediate suppliers, serve specific customer groups and regional markets.
Threat of New Entrants: Low
Multi-step chlorination and cyclopropanation chemistry requires specialised process know-how, particularly for controlling isomer ratios and impurities.
Environmental clearances, hazardous-chemical permits and effluent treatment infrastructure involve significant capital and long lead times.
Established integrated producers benefit from scale, captive demand and long-standing customer and regulatory relationships.
Bargaining Power of Suppliers: Medium
Most raw materials are commodity chemicals available from multiple suppliers, which limits individual supplier leverage.
Certain inputs, such as controlled chlorinated solvents and specific prenyl derivatives, have fewer sources and are subject to regulatory controls.
Backward-integrated producers have reduced their dependence on external suppliers for key intermediates.
Bargaining Power of Buyers: Medium
A large share of CMAC is consumed captively, so merchant buyers are mainly non-integrated pyrethroid producers and formulators.
Buyers can source from multiple Indian and Chinese producers, which increases their negotiating power in periods of oversupply.
Quality, isomer-ratio specifications and registration linkages create switching costs for buyers producing regulated actives.
Threat of Substitutes: Medium
There is no practical substitute for CMAC in the synthesis of cypermethrin, permethrin and cyfluthrin.
At the end-use level, other insecticide classes such as diamides and neonicotinoids compete with pyrethroids in some crops.
Resistance management strategies and newer net technologies reduce reliance on pyrethroid-only products in some uses.
Intensity of Competitive Rivalry: High
Several large Indian and Chinese producers compete primarily on cost in a market for generic, specification-driven products.
Capacity additions and periods of destocking have created price pressure on pyrethroid intermediates and technicals.
Trade remedies, such as China's anti-dumping duties on Indian cypermethrin, have intensified competition in third-country markets.
Threat of New Entrants: Low; Process know-how, environmental clearances and capital requirements.
Bargaining Power of Suppliers: Medium; Commodity inputs but some controlled and concentrated reagents.
Bargaining Power of Buyers: Medium; High captive use; multiple merchant sources; specification-based switching costs.
Threat of Substitutes: Medium; No substitute in synthesis; competing insecticide classes at end-use level.
Intensity of Competitive Rivalry: High; Cost-based competition between Indian and Chinese producers; trade measures.
Market estimates by geography (2032)
InsightAsia Pacific leads with $24.00M by 2032, while Middle East & Africa is projected to grow fastest at a 7.9% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2022 | 2025 | 2032 | CAGR | SHARE |
|---|---|---|---|---|---|
| North America | $1.07M | $1.37M | $1.74M | 4.9% | 6% |
| Europe | $1.44M | $1.82M | $2.29M | 4.7% | 7% |
| Asia Pacific | $13.62M | $18.14M | $24.00M | 5.8% | 78% |
| Latin America | $1.01M | $1.43M | $1.99M | 7.0% | 6% |
| Middle East & Africa | $0.33M | $0.48M | $0.70M | 7.9% | 2% |
| Total | $17.47M | $23.24M | $30.71M | 5.8% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$30.71M
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Cypermethrin | $20.75M | 5.3% | 68% |
| Permethrin & Others | $9.97M | 7.0% | 32% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Cypermethric Acid Chloride Market covering market dynamics, competitive landscape, and strategic outlook.
The Cypermethric Acid Chloride Market market is projected to reach $30.71M by 2032, growing at 5.8% CAGR. The Cypermethrin segment holds the largest share.
Demand for cypermethric acid chloride is shaped by the economics of the synthetic pyrethroid industry. As an intermediate with no significant end use outside pyrethroid synthesis, CMAC demand follows the production of cypermethrin, permethrin and related actives, which in turn depends on crop protection demand, vector-control programmes, regulatory decisions and the competitive dynamics between Indian and Chinese producers. The growth factor analysis in Section 4.2 summarises the main macro and micro factors and their expected impact over the forecast period. The impact scores shown are analyst assessments on a scale of 1 to 10, where a higher score indicates a stronger influence on the market in the period concerned.
Sustained Demand for Generic Cypermethrin in Crop Protection
Cypermethrin remains one of the most widely used broad-spectrum insecticides in the world. It is off-patent, effective against lepidopteran and sucking pests at low application rates, and inexpensive relative to newer chemistries, which makes it a mainstay in cotton, vegetables, pulses, rice, maize and soybean across Asia, Latin America and Africa. Smallholder agriculture in India, Southeast Asia and Africa in particular continues to rely on low-cost generic insecticides, and cypermethrin is frequently combined with other actives such as chlorpyrifos or neonicotinoids in pre-mix formulations. Because every kilogram of cypermethrin and its isomer-enriched variants requires CMAC as the acid-side intermediate, steady agricultural demand for cypermethrin translates directly into CMAC consumption. This is reflected in the Cypermethrin segment, which accounts for USD 14.52 Million of CMAC demand in 2025 and is expected to reach USD 20.75 Million by 2032. Population growth, the need to reduce crop losses to pests and the expansion of cultivated area under high-value crops are expected to sustain this demand through the forecast period.
Public Health, Household and Veterinary Applications of Pyrethroids
Pyrethroids are the backbone of insecticide-treated nets used in malaria prevention. According to the World Health Organization, more than 2 billion insecticide-treated nets have been distributed since 2005, and all of them have been treated with pyrethroids. Permethrin is the active ingredient in long-lasting insecticidal nets such as the WHO-prequalified OLYSET Net, while alpha-cypermethrin, which is made from high-cis CMAC, is widely used in other net designs. Beyond nets, permethrin is used in mosquito adulticiding, indoor residual and space spraying, the treatment of clothing and military uniforms, household insecticide products, and veterinary ectoparasiticides for livestock and companion animals. Permethrin is also used in human medicine for the treatment of scabies and head lice. These non-agricultural uses are less exposed to crop cycles and commodity prices, and they underpin the faster growth of the Permethrin & Others segment, which is projected to grow at a CAGR of 6.94% over 2026–2032.
Capacity Additions and Backward Integration in India
Indian pyrethroid producers have invested heavily in new capacity and backward integration since 2022. Meghmani Organics commenced production at a multi-product insecticide plant at Dahej in November 2022. Tagros Chemicals India received environmental clearance in 2023 to expand its pesticide technical and intermediate facility at Cuddalore, Tamil Nadu. Heranba Industries, through its subsidiary Heranba Organics, began commercial production at its Saykha facility in Gujarat in April 2025. In the same month, Gharda Chemicals received environmental clearance from India's Ministry of Environment, Forest and Climate Change for a large integrated agrochemicals and intermediates complex at Dahej. These projects increase the ability of Indian producers to make CMAC and other intermediates in-house rather than importing them, improving cost competitiveness and supply security. Government policy encouraging domestic manufacturing of chemical intermediates and reduced reliance on imports further supports this investment cycle, which is reflected in India's country-level CAGR of 8.01%.
Shift towards High-Purity and Isomer-Enriched Grades
Pyrethroid producers increasingly favour isomer-enriched actives such as alpha-cypermethrin and beta-cypermethrin, which deliver comparable efficacy at lower application rates. Producing these actives efficiently requires CMAC with a high assay and a controlled cis:trans ratio. Leading producers now offer high-cis CMAC grades alongside standard material; for example, Gharda Chemicals markets standard, high-cis and low-cis grades, and Heranba Industries markets a high-cis grade. Product specifications published by the FAO/WHO Joint Meeting on Pesticide Specifications, together with registration requirements in export markets, also place emphasis on impurity profiles of technical-grade actives, which encourages the use of higher-purity intermediates. As a result, the 98% & Above segment is projected to grow at a CAGR of 6.08%, faster than the 4.37% expected for the Below 98% segment.
Supply Realignment following Trade Remedies
China imposed definitive anti-dumping duties on imports of cypermethrin from India with effect from May 2025, at rates ranging from 48.4% to 166.2% for a period of five years. The measure followed an application by Jiangsu Yangnong Chemical on behalf of the Chinese industry. While it restricts Indian access to the Chinese market, it encourages Indian producers to develop alternative export destinations in Latin America, Africa, Southeast Asia and other regions, and prompts buyers worldwide to diversify sourcing between Indian and Chinese suppliers. Producers able to supply CMAC and pyrethroid technicals reliably from more than one country are well placed to benefit from this realignment.
Growth in Latin America and Middle East & Africa
Latin America and Middle East & Africa are the fastest-growing regions, with CAGRs of 6.94% and 7.73% respectively. In Latin America, large soybean, cotton, corn and sugarcane areas in Brazil and Argentina sustain demand for low-cost insecticides, and Brazil's new pesticide law (Law No. 14,785 of 2023) is intended to streamline the registration process. In Africa, malaria vector-control programmes and the expansion of commercial agriculture support pyrethroid use, while Gulf states rely on pyrethroids for urban pest and public health vector control. Suppliers that secure product registrations and distribution partnerships in these regions can capture above-average growth.
Value Addition through Specialty Grades and Integrated Chains
There is an opportunity for producers to differentiate through high-cis and low-cis CMAC grades tailored to specific downstream actives, and through integration across both halves of the pyrethroid molecule: the acid side (CMAC) and the alcohol side (3-phenoxybenzaldehyde and 3-phenoxybenzyl alcohol). Integrated producers such as Hemani Industries, which manufactures both CMAC and 3-phenoxybenzaldehyde, can offer cost and supply-security advantages to customers. Merchant supply of specialty CMAC grades to non-integrated formulators and contract manufacturers in regions without local production is a further avenue for growth.
Regulatory Restrictions on Pyrethroids in Developed Markets
Regulatory scrutiny of pyrethroids is tightening in Europe and North America. In the European Union, permethrin has not been approved for use in plant protection products since authorisations were withdrawn under Commission Decision 2000/817/EC. Cypermethrin was renewed by Commission Implementing Regulation (EU) 2021/2049 until 31 January 2029, but as a candidate for substitution and with requirements for confirmatory data, while the approval of alpha-cypermethrin was not renewed under Regulation (EU) 2021/795. In the United States, the Environmental Protection Agency's registration review of pyrethroids has introduced ecological risk mitigation measures addressing spray drift and runoff. These measures constrain volume growth in developed markets and help explain the slower CAGRs of Europe (4.65%) and North America (4.84%).
Insect Resistance and Competition from Newer Chemistries
Widespread use of pyrethroids over several decades has led to resistance in important agricultural pests and disease vectors. The World Health Organization identifies pyrethroid resistance as the most widely recognised threat to the effectiveness of insecticide-treated nets, and in March 2023 it recommended pyrethroid-chlorfenapyr nets over pyrethroid-only nets in areas where mosquitoes have become resistant. In agriculture, newer insecticide classes such as diamides and other modes of action are displacing pyrethroids in some high-value crops. Although combination products often still contain a pyrethroid, resistance limits the growth potential of pyrethroid-only products and therefore of CMAC demand.
Environmental Compliance and Process-Safety Costs
CMAC production involves chlorinated reagents and solvents, cyclopropanation chemistry and acid chloride formation with chlorinating agents, generating acidic gases and chlorinated effluents that require careful treatment. Some established routes use carbon tetrachloride, an ozone-depleting substance whose use as a feedstock is permitted but controlled under the Montreal Protocol. Following serious industrial accidents, including the March 2019 explosion at the Xiangshui chemical park in Jiangsu, Chinese authorities closed or relocated many chemical producers. Stricter environmental clearances, effluent norms and process-safety requirements in both China and India increase capital and operating costs and can delay new capacity.
Trade-Driven Realignment of Pyrethroid Supply
The cypermethrin anti-dumping case between China and India has made trade policy a central factor in competitive positioning. Duty rates differ by company, from 48.4% for Tagros Chemicals India to 166.2% for UPL and for producers not individually examined, creating differences in market access among Indian suppliers. The trend is towards regionally diversified supply chains and closer monitoring of trade measures by buyers.
Deeper Backward Integration
Producers are integrating further upstream into basic chlorination, chlor-alkali and aromatic intermediates. Gharda Chemicals' planned Dahej complex includes chlor-alkali and captive power, while Jiangsu Yangnong Chemical has been building a new production base at Huludao in Liaoning province. Integration reduces exposure to raw material price swings and supply interruptions.
Price Volatility and Margin Pressure
Prices of generic pyrethroid technicals and intermediates have been volatile since 2022, moving from elevated levels during supply disruptions to a period of destocking and price pressure, followed by recovery in some products. Industry reports indicated quarter-on-quarter increases of more than 15% in Chinese cypermethrin technical prices in the second quarter of 2026, linked partly to higher petrochemical costs. Volatility of this kind complicates contracting and compresses margins for non-integrated producers.
Sustainability and Regulatory Data Requirements
Regulators increasingly require data on endocrine disruption, environmental fate and impurities for pyrethroid actives, as illustrated by the confirmatory data requirements attached to the EU renewal of cypermethrin. Meeting these requirements raises the cost of maintaining registrations and favours producers with strong regulatory capabilities, while producers must also invest in effluent treatment, solvent recovery and emission control to meet sustainability expectations of multinational customers.
The value chain for cypermethric acid chloride extends from basic petrochemical and chlorine-based raw materials to the end users of synthetic pyrethroid insecticides. Value is added at each stage through chemical transformation, quality control and regulatory compliance.
Mar 2022: Hemani Industries Ltd; Corporate / IPO; Filed a draft red herring prospectus for a proposed INR 2,000 crore initial public offering, with plans for new plants at Saykha, Gujarat.
Nov 2022: Meghmani Organics Ltd; Expansion; Commenced production at a backward-integrated multi-product insecticide plant at Dahej, Gujarat, with capacity of 5,000 TPA.
Mar 2023: Tagros Chemicals India Pvt. Ltd.; Expansion; Received environmental clearance to expand its pesticide technical and intermediate facility at SIPCOT Panchayankuppam, Cuddalore, Tamil Nadu.
Apr 2024: Jiangsu Yangnong Chemical Co., Ltd; Trade Action; Filed an anti-dumping application on behalf of the Chinese industry against cypermethrin imported from India; China's Ministry of Commerce initiated the investigation in May 2024.
Apr 2025: Heranba Industries Ltd; Expansion; Subsidiary Heranba Organics commenced commercial production at Phase I of its Saykha, Gujarat facility.
Apr 2025: Gharda Chemicals Ltd; Expansion; Received environmental clearance from MoEF&CC for an integrated agrochemicals and intermediates complex at Dahej-II, Gujarat, including chlor-alkali and captive power.
May 2025: Gharda, UPL, Meghmani, Heranba, Bharat Rasayan, Tagros; Trade Action; China imposed definitive five-year anti-dumping duties of 48.4% to 166.2% on cypermethrin imported from India.
2025: Jiangsu Yangnong Chemical Co., Ltd; Expansion; Phase I of its Liaoning Youchuang base at Huludao reached design capacity, and Phase II was mechanically completed ahead of plan for start-up in 2026.
Jan 2026: Heranba Industries Ltd; Expansion; Subsidiary Mikusu India approved the formation of a subsidiary in the UAE to strengthen international trading.
Apr 2026: Meghmani Organics Ltd; Restructuring; Board approved a scheme to amalgamate subsidiaries Kilburn Chemicals and Meghmani Crop Nutrition into the parent company.
Political Factors
Trade remedies such as China's anti-dumping duties on Indian cypermethrin influence export flows and competitive positions.
Government support for domestic manufacturing of chemical intermediates in India encourages capacity investment.
Public funding for malaria and vector-control programmes sustains institutional demand for pyrethroid-treated products.
Economic Factors
Prices of CMAC are linked to petrochemical and chlor-alkali feedstock costs, which are subject to volatility.
Farm incomes and crop prices influence spending on crop protection in price-sensitive markets.
Exchange-rate movements affect the competitiveness of Indian and Chinese exporters.
Social Factors
Rising awareness of vector-borne diseases such as malaria and dengue supports demand for insecticide-treated nets and household insecticides.
Consumer and retailer concerns about pesticide residues encourage lower-dose, isomer-enriched products.
Growth of pet ownership supports demand for permethrin-based veterinary products.
Technological Factors
Advances in isomer separation and stereoselective synthesis enable high-cis CMAC for alpha- and beta-cypermethrin.
Process intensification, solvent recovery and continuous processing reduce costs and effluent loads.
Development of combination products and new net technologies changes the role of pyrethroids in vector control.
Environmental Factors
Pyrethroids are highly toxic to aquatic organisms and bees, prompting drift and runoff mitigation requirements.
Use of chlorinated reagents and ozone-depleting feedstocks is subject to strict controls.
Effluent treatment and hazardous waste management are critical to obtaining and retaining operating permits.
Legal Factors
Periodic re-evaluation of pyrethroid approvals in the EU and U.S. creates regulatory uncertainty.
Registration data requirements, including endocrine disruption data, raise compliance costs.
Environmental clearance and process-safety laws govern the siting and expansion of production facilities.
Profiles of 103 companies operating in the Cypermethric Acid Chloride Market market, including revenue, employee count, and market positioning where available.
Showing 103 of 103 companies
Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).
DuPont de Nemours today is a focused, roughly USD 7 bn-revenue multi-industry company. It is no longer the diversified chemical conglomerate of its heritage. After a decade of portfolio surgery, the company consists of two segments: **Healthcare & Water Technologies (about 47% of FY2025 sales):** Tyvek® medical packaging and protective garments, specialty medical device components (Spectrum, Donatelle), and the FilmTec™ / Amberlite™ water purification franchise. **Diversified Industrials (about 53%):** Building envelope products (Tyvek® house wrap, Styrofoam™, Corian®) and engineered industrial technologies (Molykote®, Vespel®, Betaseal™/Betaforce™ adhesives, Cyrel® printing plates). The company earns a premium-specialty margin profile: operating EBITDA margin was 23.8% in FY2025, with guidance of about 24.5% for FY2026. Management targets 3–4% organic growth, 150–200 bps of margin expansion and 8–10% adjusted EPS CAGR through 2028, supported by a lightly levered BBB+/Baa1 balance sheet. The principal overhang is legacy PFAS liability, shared with Chemours, Corteva and Qnity under contractual arrangements. The principal opportunity is a cleaner, higher-growth healthcare/water mix and capital redeployment. --- **Company's own description (FY2025 10-K, Item 1).** DuPont describes itself as a leading provider of advanced solutions that improve everyday life across healthcare, water, construction and industrial markets. It emphasizes helping customers advance their technology pipelines, from clean water to medical packaging that enhances safety and performance. It names its competitive strengths as: - proprietary product and process technologies; - robust application-development pipelines; - well-known brands; - customer intimacy; - global manufacturing and local service capability. **Independent characterization.** DuPont is now best understood as a specialty engineered-materials and components company with four businesses of roughly comparable scale: **Business model and revenue model.** - Revenue is overwhelmingly product sales: materials, components, membranes, resins, garments and plates. Some engineered systems and modules are sold in Water. - There is no material subscription or licensing revenue. Trade secrets may be licensed occasionally (10-K, Intellectual Property). - The contract manufacturing and design services of Spectrum and Donatelle (medical devices) add a design-in / build-to-print services element, but are recognized as product revenue. - Seasonality: North American Building Technologies demand peaks in Q2–Q3. **Value-chain position.** DuPont sits mid-stream as a Tier-1/Tier-2 supplier. It converts purchased raw materials (polyolefins, specialty monomers, resins, silicones, polymers) into engineered materials, membranes and components. These are specified into customers' finished products: medical devices, sterile packaging, water plants, building envelopes, aircraft, vehicles and print packaging. **Customer types.** - Medical device OEMs and sterile packaging converters - Biopharma manufacturers - Industrial end users and EPC/OEM water-system integrators - Municipalities and desalination operators (via integrators) - Builders, contractors and distributors (e.g., Corian® distribution through Hallmark and Parksite) - Automotive and EV OEMs and Tier-1s - Aerospace OEMs - Printing and packaging converters Most products are sold through DuPont's own sales organization, with distributors used for some lines (10-K, Distribution). **End markets.** Healthcare (medical devices, packaging, biopharma, PPE), water (industrial, municipal/desalination, life sciences, microelectronics UPW), construction (residential, non-residential, repair/remodel) and industrial (aerospace, automotive/EV, printing and packaging, general industrial).
Nippon Soda is a mid-cap, diversified Japanese chemical group founded in 1920 as a chlor-alkali producer and progressively re-shaped into a portfolio anchored by two high-value franchises: research-based crop protection (Agri Business, 35% of FY3/26 sales) and specialty "Chemical Materials" (25%), complemented by lower-margin but stable trading/logistics, plant engineering and environmental-recycling businesses. Its crown jewels are niche, high-barrier products in which it holds globally relevant positions — the pharmaceutical excipient NISSO HPC (hydroxypropyl cellulose), liquid polybutadiene NISSO-PB for AI-server copper-clad laminates, KrF photoresist polymer VP-POLYMER, and proprietary agrochemicals such as Mospilan (acetamiprid) and Topsin-M. With FY3/26 net sales of JPY 152.1 billion, record net profit of JPY 18.3 billion, an equity ratio of ~66.6%, and a 50%+ total shareholder return policy, the company is a conservatively financed, R&D-led specialty player now pivoting toward healthcare (including animal health) and advanced ICT materials under its Stage III plan to FY3/30. --- ### Company's own description According to its Stage III medium-term plan (May 2026), Nippon Soda describes its mission as creating new value through the power of chemistry, and frames the group as supporting everyday life through chemical products and services across four "material" fields: Agriculture (securing food and sustainable agriculture), Healthcare (healthy life for all people), Environment (toward a resource-recycling society) and ICT (chemical functions for IT devices). The Yuho describes the parent's business as manufacturing, processing and marketing of industrial chemicals, synthetic resins and plastics, dyes, pharmaceuticals, agrochemicals, veterinary pharmaceuticals and other chemical products. ### Business model and revenue model Nippon Soda's revenue is overwhelmingly product-based (manufactured chemical sales), with secondary service revenues from logistics (warehousing, transport, customs brokerage), engineering/EPC contracts and waste treatment. There is no material subscription revenue. Licensing/active-ingredient supply is embedded in Agri Business: the company supplies proprietary active ingredients (AIs) to global majors and sells formulated products through its own overseas network and partners. The revenue mix by nature (approximation from FY3/26 segment data; company does not disclose a product/service split): *Note: the above split is an analytical characterization; the company does not report revenue by nature.* ### Value-chain position **Agri Business:** fully integrated R&D-type agrochemical originator — chemical synthesis, biological/safety research, formulation research, field evaluation, AI manufacturing (including via Nisso Namhae Agro in Korea) and formulation, registration and global marketing (Stage III plan). The company emphasizes that R&D-type agrochemical originators are largely limited to five overseas majors plus Japanese firms, and that Japanese originators punch above their weight in new AI discovery. **Chemical Materials:** upstream chlor-alkali (caustic soda, chlorine, hydrochloric acid) feeding downstream fine/specialty chemistry (living anionic polymerization for NISSO-PB and VP-POLYMER; cellulose derivatization for HPC; penem API synthesis). **Trading & Logistics:** captive and third-party distribution (Nisso Shoji) and specialized hazardous/pharma logistics (Sanwa Soko, Sanso Unyu). **Engineering:** fine-chemical-type EPC (Nisso Engineering) and civil works (Nisso Kensetsu). **Eco Solutions:** waste treatment, zinc recovery from electric-arc-furnace dust, sulfuric acid recycling (Nisso Metallochemical). ### Customer types and end-markets Customers include global agrochemical majors and distributors, farmers' cooperatives (via channels), generic and innovator pharmaceutical companies and supplement makers (HPC, SSF, faropenem API), copper-clad-laminate (CCL) and semiconductor-materials producers (NISSO-PB, 1,2-SBS, VP-POLYMER), thermal-paper manufacturers (color developers), battery-materials producers, industrial users of commodity chemicals, steelmakers (EAF dust treatment), and public/private construction clients (Engineering). End-markets: crop protection (fruit & vegetables first, expanding to grains), pharmaceuticals/nutraceuticals, semiconductors/electronics (AI servers, HBM, automotive chips), infrastructure, and environmental services. ### Independent characterization Nippon Soda is best understood as two engines and three stabilizers. The engines — Agri Business and specialty Chemical Materials — generated roughly 75% of FY3/26 segment operating profit (JPY 11.2 billion of JPY 14.97 billion before adjustments) on 60% of sales. Agri is cyclical and FX-sensitive (65.7% overseas sales ratio in FY3/26), while Chemical Materials has been structurally re-rated from a ~5–6% margin business to ~15–17% after exiting commodity lines (metallic sodium via Alkaline S.A.S., NISSO HI-CHLON, phenol-based color developers, sodium cyanide). The stabilizers (Trading & Logistics, Engineering, Eco Solutions) are low-growth and modest-margin but add scale and cash. A further, often-overlooked profit pillar is equity-method income (JPY 6.06 billion in FY3/26, chiefly Iharabras in Brazil), which made ordinary profit (JPY 22.99 billion) much larger than operating profit and is highly FX-sensitive (BRL/USD).
RPM International is a holding company for more than a dozen semi-autonomous specialty-chemicals franchises. These businesses make coatings, sealants, roofing, concrete admixtures, flooring, fireproofing and building-envelope systems, mostly for maintenance, repair and restoration rather than new construction. Its brand portfolio is unusually deep for a USD 7.9 billion company: Rust-Oleum, DAP, Zinsser, Varathane and The Pink Stuff on the consumer side; Tremco, Euclid, Dryvit, Nudura, Kalzip, Stonhard, Carboline and Fibergrate on the professional side. Each brand holds a leading position in a niche that larger diversified coatings groups do not dominate. Since 2018 RPM has run successive operational-improvement programs (MAP to Growth, MAP 2025, and now "MAP 3.0"). These have lifted gross margin from about 36% (FY2022) to about 41% (FY2026) and moved the group from a loose federation toward a centrally coordinated operating company. RPM is a disciplined, dividend-growing compounder with 52 consecutive annual dividend increases. Its growth vectors are engineered building systems, emerging markets (the "Platform" model) and bolt-on M&A. --- ### Company's own description (FY2026 Form 10-K, Item 1) RPM describes itself as follows: its subsidiaries manufacture, market and sell specialty chemical product lines, including high-quality specialty paints, infrastructure rehab and repair products, protective coatings, roofing systems, sealants and adhesives. These products focus on the maintenance and improvement needs of the construction, industrial, specialty and consumer markets. Footprint as of 31 May 2026: - Products marketed in about 167 countries and territories. - Manufacturing in about 120 locations across 22 countries. - About 31% of sales generated internationally: foreign operations 29.8% of net sales, plus direct U.S. exports of 0.9%. The press-release boilerplate calls RPM "a world leader in specialty coatings, sealants, building materials and related services." ### Business model RPM's model has four defining features. - **Decentralised entrepreneurial structure, becoming more integrated.** The founder's philosophy, still quoted in the 2026 proxy, is: "Hire the best people you can find. Create an atmosphere that will keep them. Then let them do their jobs." Operating companies historically kept their own brands, sales forces and ERP systems. The MAP programs are deliberately centralising procurement, manufacturing, accounting and IT. The stated goal is to consolidate more than 75 ERP systems to one platform per segment (Q4 FY2026 8-K). **Repair and maintenance bias:** Much of the portfolio serves existing assets: roof restoration, re-cover, concrete repair, corrosion control, rust prevention and DIY touch-up. That demand is less cyclical than new-build construction. The FY2026 10-K notes that re-roofing has historically accounted for over three-quarters of U.S. roofing demand. **Systems and turnkey selling:** In CPG and PCG, RPM increasingly sells integrated systems (the "Power of One" building envelope) and supply-and-apply turnkey services. Examples include Stonhard flooring installation and Weatherproofing Technologies roofing services. This captures more of each construction project's spend. **Bolt-on M&A plus organic growth:** RPM completed six acquisitions in each of FY2025 and FY2026 (FY2026 10-K Note F). ### Revenue model mix RPM does not disclose a product versus service versus licensing split. From filings, the mix is: ### Value-chain position RPM is a formulator and brand owner, positioned downstream of commodity chemical producers. It buys petroleum-derived resins, solvents, pigments, minerals, metals and packaging (FY2026 10-K, Raw Materials). It is selectively backward-integrated: RPM cites expanding in-house raw material production, and Arnette Polymers makes amine curing agents and epoxy intermediates. Channels downstream include: - Mass merchants and home centres, where the single largest Consumer customer was 20% of Consumer sales in FY2026. - Hardware and paint stores. - Distributors. - Contractors and specifiers. - Direct sales to industrial plant owners, public institutions and infrastructure agencies. ### Independent characterisation RPM is best understood as a portfolio of niche category leaders with a structural margin-improvement story layered on top. The professional segments (CPG and PCG) are about 66% of sales and supply the growth. In FY2026 they posted record results driven by high-performance buildings, data centres, infrastructure, fireproofing and concrete admixtures. In Q1 FY2027, emerging-market regions grew more than 20%. The Consumer segment is about 34% of sales. It is a cash-generative but volume-challenged DIY business. Organic Consumer sales fell 0.8% in Q4 FY2026 and 4.7% in Q2 FY2026. They recovered to +5.2% in Q1 FY2027 on shelf-space wins and pricing. The equity debate therefore centres on three questions: 1. Can MAP savings and pricing protect margins against renewed raw-material inflation linked to the Middle East conflict? 2. Is the Q1 FY2027 CPG slowdown temporary? 3. Will the 9 November 2026 investor day credibly frame the next margin plan?
3 interactive charts drawn from the Cypermethric Acid Chloride Market dataset — market size, regional splits and each segment breakdown. Open one to read its full data table and download it.
Global Cypermethric Acid Chloride Market By Purity
Global Cypermethric Acid Chloride Market By Downstream Product
Global Cypermethric Acid Chloride Market By Region
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Million)
